Table 2.

NICE guidelines for DOACs.³ ACS, acute coronary syndrome; DVT, deep vein thrombosis; NICE, National Institute for Health and Care Excellence; PE, pulmonary embolism. Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs). All rights reserved. Subject to notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication

Indication	Apixaban	Rivaroxaban	Dabigatran etexilate
VTE prevention after elective hip or knee replacement	Licenced for this indication	Licenced for this indication	Licenced for this indication
Secondary prevention or management of DVT or PE	Licenced for this indication	Licenced for this indication	Licenced for this indication
Stroke and systemic embolism prevention in patients with non-valvular AF	Possible treatment in specific circumstances	Possible treatment in specific circumstances	Possible treatment in specific circumstances
Prevention of adverse outcomes after acute management of ACS with increased biomarkers	Not licensed for this indication	Possible treatment in specific circumstances	Not licensed for this indication